Viyash Scientific Ltd

- Capex for API segment: - Around INR 60 crores spent recently by Viyash. - No major capex expected in the next 2 years for current strategic API business. - Some capex might be required for new opportunities like CDMO and complex molecules. - Capex for formulation segment: - Planning to improve pet care manufacturing capability starting possibly from FY '27, spilling into FY '28. - Expected capex of about INR 100-150 crores in FY '27-FY '28 focused on manufacturing base, predominantly in India. - Strategic investments: - Actively exploring inorganic opportunities—both small and large—that fit the global animal health strategy. - Inorganic targets include front-end expansion in Europe, new product in-licensing, manufacturing base expansion in India. - Aim to fill capability gaps and expand global animal health footprint. - Debt reduction expected by FY '27 unless impacted by inorganic deals.

- SeQuent Scientific aims for sustained double-digit revenue growth, targeting around 15% year-on-year, as demonstrated by recent quarters. - Formulation segment is expected to grow strongly, particularly in companion animal health, with plans to expand front-end presence in markets like Mexico and launch new products in Latin America (e.g., tulathromycin injection in Brazil). - API business targets maintaining an INR100 crore run rate with growth expected from FY '27 onwards, supported by new production lines and increased capacity (e.g., albendazole sales growing due to site shutdowns of competitors). - The combined entity post-merger expects robust growth driven by synergies in R&D, manufacturing optimization, and product launches, aiming for at least 20% EBITDA margin sustainability. - CDMO (Contract Development and Manufacturing Organization) business, which lagged earlier, is expected to recover and grow substantially over the next 2 years. - The company is also focused on higher-value product mix improvements to drive better margins alongside revenue growth.

- **Revenue Growth**: SeQuent expects strong top-line growth with a 15% YoY increase in Q2 FY26 revenue; Viyash anticipates over 20% CAGR in the next 3 years. - **Margin Improvement**: Continuous quarter-on-quarter gross margin improvements seen; SeQuent’s gross margins are expected to sustain close to or above 50%. - **EBITDA Margins**: Combined entity targets minimum 20%+ EBITDA margin soon, sustained beyond FY27; Q2 already showed 22% EBITDA margin for Viyash. - **Profitability**: Profit after tax nearly tripled YoY in Q2 FY26; operational efficiencies and R&D investments are expected to drive further profit growth. - **EPS**: While no explicit EPS guidance provided, overall profitability growth and margin expansion suggest positive EPS trajectory. - **Other Factors**: - Focus on product mix optimization and R&D innovation to fuel growth. - Merger synergies anticipated to foster operational leverage and financial strength. - Debt expected to be cleared by FY27 enhancing free cash flow and returns.

The transcript on page 20 of the SeQuent Scientific Limited Earnings Call does not explicitly mention the current or expected order book or pending orders figures. However, relevant insights include: - The company has seen continuous quarter-on-quarter improvement in gross margins, suggesting steady operational performance. - There is visible growth in product mix and new product launches contributing to sales growth. - The API business has good visibility to grow from Q4 onwards with a new production line established for increased capacity. - The firm is focusing on expanding the companion animal segment and CDMO business which is expected to grow in the next 2-3 years. - The merger completion with Viyash will enhance the combined entity's reach and operational capabilities, gearing for sustainable growth. No specific quantitative order book or pending order data is disclosed in the transcript.

- No explicit mention of new fundraising through debt or equity in the transcript. - Management highlighted strong free cash flow generation quarter-on-quarter. - Guidance states the company expects to be debt-free by FY 2027 unless there is a merger. - Balance sheet is described as strong and capable of supporting expansion without the need for new debt currently. - Any future inorganic growth (mergers/acquisitions) may require leverage, but no specific fundraising plan was disclosed. - No reference to raising equity capital was made during the call. - Overall, focus is on utilizing existing financial strength and cash flows to fund growth and investments.